Purpose We investigated whether treatment with the selective cannabinoid receptor 2
agonist GP1a would ameliorate the severity of experimental cystitis. We determined the …

The cannabinoid type 2 receptor (CB2) has previously been implicated as a regulator of
tumor growth, bone remodeling, and bone pain. However, very little is known about the role …

Treating Cancer-induced bone pain (CIBP) continues to be a major clinical challenge and
underlying mechanisms of CIBP remain unclear. Recently, emerging body of evidence …

Cannabinoids have been shown to exert analgesic and anti-inflammatory effects, and the
effects of cannabinoids are mediated primarily by cannabinoid receptors 1 and 2 (CB1and …

Up to 90% of patients with metastatic or advanced stage cancer will experience significant
cancer-related pain. Approximately half or more of patients diagnosed with cancer may …

Pain, especially chronic pain, can strongly affect patients' quality of life. Cannabinoids
ponhave been reported to produce potent analgesic effects in different preclinical pain …

Objective Osteoporosis is a skeletal disease with decreased bone mass and alteration in
microarchitecture of bone tissue, and these changes put patients in risk of bone fracture. As …

Severe and poorly treated pain often accompanies breast cancer. Thus, novel mechanisms
involved in breast cancer-induced pain should be investigated. Then, it is necessary to …

INTRODUCTION: The cannabinoid receptor type 2 (CB2) is an important target for
development of drugs and imaging agents for diseases, such as neuroinflammation …

Objective Prolonged glucocorticoid treatment increases the risk of osteopenic disorders.
Bone loss and marrow fat accumulation are prominent features of glucocorticoid‐induced …